Deutsche Bank’s Adial Pharmaceuticals ADIL Stock Holding History

Deutsche Bank’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3	Closed	-$3K	–	4844
2019 Q2	$3K	Buy	+3	New	+$4.47K	﹤0.01%	5139
2019 Q1	–	Hold	0	–	–	–	5145

Other funds holding ADIL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Deutsche Bank's ADIL Position: Q3 2019 in Review

Deutsche Bank sold out of Adial Pharmaceuticals (ADIL) in Q3 2019, closing a stake of 3 shares — an estimated $3K sold.

Deutsche Bank first reported a position in ADIL in Q2 2019 and held it in 1 quarter. The position peaked at $3K in Q2 2019. 10 funds tracked by Wall St. Rank hold ADIL as of Q3 2019.

Deutsche Bank reported no remaining Adial Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Deutsche Bank sold 3 Adial Pharmaceuticals shares in Q3 2019, an estimated $3K.
Deutsche Bank first reported a position in Adial Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Deutsche Bank's Adial Pharmaceuticals position peaked at $3K in Q2 2019.
10 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q3 2019.

Based on Deutsche Bank's 13F filing for Q3 2019, filed 14 Nov 2019.